Düsseldorf, 16 December 2025 – The European medical cannabis and industrial hemp group SYNBIOTIC SE (ISIN: DE000A3E5A59 | WKN: A3E5A5) announces a strategic equity investment. The specialised cannabis and hemp equity fund CANSOUL – Hanf Aktien Global (WKN: A2PX8U | ISIN: LI0514446843) has acquired a stake in SYNBIOTIC as part of a cash capital increase.

CANSOUL is a specialised equity fund investing across the entire global value chain of the hemp and cannabis industry. Its holistic investment approach covers cultivation, research, technology, extraction and distribution through to pharmaceutical development. The fund invests globally in leading industry players and diversifies across medical cannabis, industrial hemp, CBD and — in legally regulated jurisdictions — the recreational market. CANSOUL’s objective is to identify early-stage trends in infrastructure, patents and licences that fundamentally drive long-term market development.

Daniel Stehr, Founder of the CANSOUL Fund, commented: “Our decision to participate in the capital increase of SYNBIOTIC is based on an attractive fundamental valuation and the successful internal restructuring of the Group. SYNBIOTIC holds assets with strong strategic differentiation, including an import licence and GMP manufacturing authorisation for medical cannabis, as well as its shareholding in GOC Nexus with its patented cold plasma process for GMP sterilisation — a clear technological advantage in quality enhancement. Combined with market leadership in industrial hemp and a management team with deep regulatory expertise, SYNBIOTIC offers an attractive risk-return profile.”

The transaction marks the starting point of a long-term partnership. As one of the leading players in regulated cannabis investments, CANSOUL underscores the attractiveness of SYNBIOTIC’s diversified business model.

“The investment via the capital increase represents the beginning of a strategic engagement. The SYNBIOTIC position is now being built within the CANSOUL fund’s portfolio and is explicitly designed as a long-term investment to accompany the growth potential of the diversified platform over the coming years,” Stehr added.

Daniel Stehr and Daniel Kruse, CEO of SYNBIOTIC, jointly stated: “Germany is facing significant developments in the growth markets of cannabis and industrial hemp. However, those expecting a rapid ‘coffee shop boom’ are likely to be disappointed. We realistically see commercial recreational use materialising only over the next five to ten years. The near-term growth drivers lie in medical cannabis and industrial hemp — sectors that will expand substantially for healthcare and environmental policy reasons.”

Active on Intercontinental Capital Markets and at the Political Level

CANSOUL’s investment also reflects SYNBIOTIC’s increased visibility at key intercontinental capital market events.

At a Talman House event in London, Daniel Kruse and Patrick Hirschauer, from SYNBIOTIC’s management team, met numerous international investors and industry representatives. According to Hirschauer, sentiment was “exceptionally optimistic, with sustained and growing interest in the European cannabis market.”

At the German Equity Forum in Frankfurt, Supervisory Board member Dr Andreas Wuzik and Hirschauer presented SYNBIOTIC to a broad institutional audience. “Frankfurt felt like ‘Dragons’ Den’ — but with institutional investors,” Hirschauer noted. “The questions were critical, highly professional and very constructive. It was extremely valuable for us, as we were able to position SYNBIOTIC beyond sector-specific filters and further sharpen our business model in an industrial context.”

Daniel Kruse, CEO of SYNBIOTIC, participated in the inaugural meeting of the Foreign Trade Working Group on 26 November 2025 in Berlin with Federal Minister for Economic Affairs Reiche. He commented positively: “The meeting demonstrated that Germany’s domestic and foreign economic challenges are being recognised and that promising solutions — including new growth markets — are on the agenda. I am already looking forward to the next round of discussions.”

Publisher
SYNBIOTIC SE
Daniel Kruse
CEO
Münsterstraße 336
40470 Düsseldorf
Germany
www.synbiotic.com

Media
Rüdiger Tillmann
SYNBIOTIC Public Relations Manager
Email ruediger.tillmann@synbiotic.com
Mobile +49 170 9651451
c/o JOLE.group

About SYNBIOTIC
SYNBIOTIC is a listed group of companies in the medical cannabis and industrial hemp sector with a buy-and-build investment strategy focussed on Europe. The Group covers the entire value chain from cultivation to production and retail – from the field to shelf. The subsidiaries’ core businesses are research and development, production and the commercialisation of medical cannabis, industrial hemp and CBD products. SYNBIOTIC is pursuing a clear pan-European strategy of further expanding its business areas in order to cover the relevant growth markets while minimising risks and increasing opportunities for investors through diversification.

Ad hoc announcement

Vitruvia Medical AG

December 15, 2025

Vitruvia Medical AG successfully completes capital increase and strengthens its financial structure

Vitruvia Medical AG announces that a capital increase was successfully completed on December 15, 2025. The newly created capital was used in full to repay the convertible bond due at the beginning of December.

This measure strengthened the company’s equity and significantly reduced its debt. The improved capital structure secures the long-term financing of Vitruvia Medical AG and contributes significantly to the company’s economic stability.

The Board of Directors of Vitruvia AG

Relief Therapeutics and NeuroX Complete Business Combination and Form MindMaze Therapeutics

GENEVA (Dec. 15, 2025) – MindMaze Therapeutics Holding SA (SIX: MMTX) (MindMaze Therapeutics or the Company) announced today the completion of its business combination with NeuroX Group SA (NeuroX), a commercial-stage company delivering evidence-based, precision digital treatments for neurological diseases. The newly combined entity now operates under the name MindMaze Therapeutics Holding SA.

The closing follows the signing of a definitive business combination agreement in October 2025 and subsequent shareholder approval at the Company’s extraordinary general meeting in November. The transaction establishes a fully integrated company with a first-of-its-kind ecosystem, uniting precision digital neurotherapeutics, pharmacological treatments, cutting-edge devices, data, and an AI-powered platform, positioned to redefine neurological care and change patient lives.

“Neurological diseases are one of the leading causes of disability globally,” said Olaf Blanke (MD), member of the Board of Directors, Professor of Neuroscience and Cognitive Neuroprosthetics at the Swiss Federal Institute of Technology (EPFL) and Adjunct Professor at the Department of Clinical Neurosciences at the University Hospital of Geneva. “The situation is worsening due to aging populations, with 1 in 6 people expected to develop a neurological disease, making the need for effective, scalable solutions more urgent than ever. While neuro-rehabilitation requires intensive, repetitive training for functional recovery, traditional healthcare systems often fail to deliver adequate therapy, leaving millions of patients without optimal treatment. MindMaze Therapeutics seeks to address this gap by providing clinically proven neurotherapeutics to support their recovery journey, from hospital to rehab center to their home.”

“Today begins a new chapter for MindMaze Therapeutics,” commented Walid Hanna, Chairman of the Board of Directors of MindMaze Therapeutics. “The company is founded on clinically validated innovation, and driven by a mission to transform neurological care, addressing a critical and persistent gap in motor and cognition restorations in neurological conditions. We are now focused on advancing our precision neurotherapeutics platform to deliver impact at scale. Relief’s complementary capabilities and biopharmaceutical assets strengthen our growth strategy, supporting both drug-digital integration and expanding development opportunities.”

MindMaze Therapeutics acquired NeuroX through a share exchange in which all outstanding shares of NeuroX were contributed by its former shareholders in exchange for 140,000,000 newly issued ordinary shares of the Company. These new shares will be admitted to trading and listing on the SIX Swiss Exchange today, in accordance with the approved prospectus and applicable regulations. Effective immediately, all listed ordinary shares of the Company will trade under the updated ticker symbol MMTX. Following the transaction, the total number of outstanding shares amounts to 152,602,044, excluding treasury shares.
 

ABOUT MINDMAZE THERAPEUTICS
MindMaze Therapeutics is a Swiss-based, commercial-stage company formed in December 2025 through the business combination of RELIEF THERAPEUTICS Holding SA (Relief) and NeuroX Group SA. The Company develops and commercializes first-of-its-kind digital treatments for neurological diseases and brain disorders. Built on an advanced brain technology platform integrating software, sensors, and telehealth, its solutions are deployed globally across clinics and home settings. MindMaze Therapeutics’ clinically validated neurotherapeutics have demonstrated significant medico-economic outcomes across conditions such as stroke, Parkinson’s disease, and at-risk aging. The Company continues to expand its R&D pipeline into adjacent neurological indications, including multiple sclerosis, spinal cord injury, traumatic brain injury, and Alzheimer’s disease.

The Company also manages Relief’s preexisting portfolio of clinical and commercial biopharmaceutical assets focused on rare dermatological, metabolic, and respiratory diseases.

MindMaze Therapeutics is listed on the SIX Swiss Exchange under the ticker MMTX and quoted in the U.S. on OTCQB under RLFTF and RLFTY.

For more information, visit www.mindmazetherapeutics.com.
 

CONTACT
MindMaze Therapeutics Holding SA
Jeremy Meinen
Chief Financial Officer
ir@mindmaze.com
 

DISCLAIMER
This press release contains forward-looking statements, which may be identified by words such as “believe,” “assume,” “expect,” “intend,” “may,” “could,” “will,” or similar expressions. These statements are based on current plans and assumptions and are subject to risks and uncertainties that could cause actual results, financial condition, performance, or achievements to differ materially from those expressed or implied. Such factors include, among others, business, economic, financial, regulatory, and competitive factors, as well as the Company’s ability to execute its strategy and secure sufficient resources to support its operations. This communication is provided as of the date hereof, and MindMaze Therapeutics undertakes no obligation to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

Biotech Showcase™ 2026 Returns to San Francisco During JPM Week as a Premier Destination for Dealmakers

Partnering Platform Now Open for Registration

SAN FRANCISCO — December 12, 2025 — Biotech Showcase™ returns to San Francisco during J.P. Morgan Healthcare Week, marking its 19^th year as a premier destination for global biopharma leaders to showcase their companies and technologies, build relationships, and make deals with venture investors and partners. Taking place January 12-14 and virtually January 21-22, the event will gather more than 1,200 life sciences investors and 3,200 global biopharma professionals, including representatives from companies including PhRMA, BIO, Novo, Ipsen, Regeneron, and Sofinnova Investments.

Attendees can participate in one-to-one meetings with investors, partners and news media, provide corporate presentations, and engage in multiple face-to-face networking sessions. This year’s event will again seamlessly integrate with the TechBio and Seed Showcases, offering unmatched opportunities for investors and partners to engage with companies across the full spectrum of life science innovation. Virtual attendees will benefit from partnering privileges in addition to on-demand access to company showcases and session recordings. Access to extensive on-demand programming, including recordings of sessions and workshops is provided to all attendees.

“Reflecting the significant uptick in M&A and funding across the life sciences ecosystem, Biotech Showcase is set to deliver a record-breaking year in terms of networking and deal-making opportunities,” said Sara Jane Demy, Founder and CEO of Demy-Colton. “This year we’re anticipating more than 300 presenting companies, 1,200 investors and a projected 6,000+ one-to-one meetings, making Biotech Showcase the largest and most influential investor conference for private, micro-cap and mid-cap biotechnology companies, as well as TechBio companies, venture investors, and partnering companies.”

The 2026 agenda will feature discussions on trending topics, including:

• Strategic Adaptation to the New Policy Landscape
• Opportunities in Asia & Europe
• The Pharma Perspective
• The Future of Healthcare Access & Equity
• The Outlook for Biopharma Financing
• AI & Quantum Computing in Healthcare
• Investment in Women’s Health

“With a robust agenda focused on key industry trends in biopharma, and a lineup of exceptional company presentations from both public and private companies, Biotech Showcase has proven itself as the leading platform for connecting innovators and investors across the global biotech community,” Tina Elder, Global Managing Director, EBD Group US, added. “Many thanks to all our investors, speakers, sponsors, media and other attendees for enabling these important conversations that help drive the industry’s funding, collaboration and therapeutic breakthroughs.”

To register for Biotech Showcase or to apply to present or sponsor, please visit https://informaconnect.com/biotech-showcase/.

About Demy-Colton

Demy-Colton is a leading life sciences and digital health events organization at the forefront of building networks between innovative life sciences companies and industry stakeholders. Its unique events facilitate networking on a global scale, including Biotech Showcase™, BioFuture™, Global Biotech CEO Summit™, Executive Clinics™, and Demy-Colton Virtual Salons™. These events build networking communities that transcend geographical boundaries and establish ongoing, high-value relationships among the industry’s top decision-makers, investors and thought leaders. For more information, visit www.demy-colton.com. 

About Life Sciences Partnering and Investment by Informa

Our mission is to help collaborations get started across the life science value chain. Our range of partnering conferences has grown to become the largest and most productive conference platform in the industry. Each one of our landmark events held in key life science markets around the world is powered by our state-of-the-art partnering software, partneringONE®, that enables delegates to efficiently identify and engage with new opportunities via one-to-one meetings. Today our events (BIO-Europe®, BIO-Europe Spring®, Biotech Showcase™, ChinaBio® Partnering Forum, Asia Bio Partnering Forum, BioEquity Europe, LSX USA Congress, Investival Showcase Europe, European Lifestars Awards, Investival Showcase USA, LSX Europe Congress, LSX Nordic Congress) annually attract more than 14,000 senior life science executives who engage in over 83,000 one-to-one partnering meetings. These vital one-to-one engagements are the wellspring of deals that drive innovation in our industry.

Contacts

Katie Morris, PhD
ENTENTE Network of Companies
katiemorris@ententeinc.com

MC Services, Inc.
Laurie Doyle
Phone: +1-339-832-0752
E-mail: EBDGroup@mc-services.eu

Media release

PolyPeptide and Lupin Manufacturing Solutions Form Strategic Alliance to Meet Growing Demand for Peptide Supply in Metabolic Therapies

Baar, 12 December 2025 – PolyPeptide Group AG (SIX: PPGN), a global CDMO for peptide-based APIs, and Lupin Manufacturing Solutions Limited (LMS) have formed a strategic alliance to enhance supply chain resilience, improve operational efficiency, and support the long-term growth of both organizations.

Through this alliance, PolyPeptide will broaden its sourcing options for key materials, establishing a more robust and flexible supply chain for peptide manufacturing. The agreement sets a framework for long-term cooperation, including integrated procurement and supply planning for select raw materials. Both companies are committed to maintaining high standards of quality, reliability, and compliance.

“Reliability is a competitive advantage in our industry. Working with Lupin Manufacturing Solutions gives us the flexibility and supply chain depth needed to support growing customer demand, including metabolics demand,” said Dr. Stéphane Varray, Chief Commercial Officer, PolyPeptide. “When you’re enabling life-changing therapies, your supply chain must operate as a true strategic capability.”

Dr. Abdelaziz Toumi, Chief Executive Officer, Lupin Manufacturing Solutions, said, “We are delighted to announce our strategic alliance with PolyPeptide. As peptide-based therapies continue to transform the treatment landscape for metabolic and other chronic conditions, LMS is committed to ensuring reliable access to specialised materials that support large-scale commercial production. This underscores our mission to establish secure, agile, and future-ready supply pathways for innovators worldwide.”

Contact

PolyPeptide Group AG      
Corporate Communications  
Lauren Starr     
mediateam@polypeptide.com    
T: +41 43 502 0580    

PolyPeptide Group AG
Investor Relations
Tim Brandl 
investorrelations@polypeptide.com 
T: +41 43 502 0580 
 

About PolyPeptide

PolyPeptide Group AG and its consolidated subsidiaries (“PolyPeptide”) is a specialized Contract Development & Manufacturing Organization (CDMO) for peptide based active pharmaceutical ingredients. By supporting its customers mainly in pharma and biotech, it contributes to the health of millions of patients across the world. PolyPeptide serves a fast-growing market, offering products and services from pre-pre-clinical to commercial stages. Its broad portfolio reflects the opportunities in drug therapies across areas and with significant exposure to metabolic diseases, including GLP-1. Dating back to 1952, PolyPeptide today runs a global network of six GMP-certified facilities in Europe, the U.S. and India. PolyPeptide’s shares (SIX: PPGN) are listed on SIX Swiss Exchange.

For more information, please visit polypeptide.com.

@PolyPeptide — follow us on LinkedIn

About Lupin Manufacturing Solutions Limited (LMS)

Lupin Manufacturing Solutions Limited, a 100% subsidiary of Lupin Limited, is a leading manufacturer of Active Pharmaceutical Ingredients (APIs) and a global Contract Development and Manufacturing Organization (CDMO) offering standalone & integrated solutions across drug substances, complex chemistry, drug product, and advanced modalities, including ADCs and peptides. Leveraging Lupin’s legacy of scientific rigor and regulatory expertise, LMS supports biopharma innovators from early development to commercial scale. With state-of-the-art facilities, a client-first approach, and a team of 250+ scientists, LMS accelerates the path to market for transformative therapies.

For more details, visit https://www.lupin.com/LMS/  or email at lmsinfo@lupin.com

Disclaimer

This media release has been prepared by PolyPeptide Group AG and contains certain forward-looking statements that reflect the current views of management. Such statements are subject to known and unknown risks, uncertainties and other factors that may cause actual developments to differ materially from those expressed or implied in this release. PolyPeptide Group AG is providing the information in this release as of this date and, except as required by applicable laws or regulations, does not undertake any obligation to update any statements contained in it as a result of new information, future events or otherwise.

Expansion of the Management Board of M1 Kliniken AG

Berlin, 11. December 2025 – The Supervisory Board of M1 Kliniken AG has appointed Ms. Katharina Zimmnau to the Executive Board of M1 Kliniken AG with effect from 10. December 2025. Ms. Zimmnau has been CFO of M1 Kliniken AG since June 1, 2025.

“I am very pleased to welcome Ms. Zimmnau to the team. With her many years of experience in accounting, controlling, and process design, she will play a key role in shaping the further development of our profitable growth trajectory”, says Attila Strauss, CEO of M1 Kliniken AG.

About M1 Kliniken AG

M1 Kliniken AG is the leading fully integrated provider of medical aesthetic services in Europe and Australia. With a clear strategic focus, high standardization, and consistent scalability, the Group currently operates 58 clinics in ten countries under the M1 Med Beauty brand. All treatments are performed exclusively by qualified physicians and adhere to uniform, high medical standards, while being offered at market-leading prices. Since late 2018, M1 has systematically driven its international expansion, which forms the basis for scalable future growth and the further development of its global market position. With the M1 Schlossklinik in Berlin, the Group operates one of Europe’s largest and most modern clinics for plastic and aesthetic surgery, featuring four operating theaters and 35 beds.

Contact:
M1 Kliniken AG
Grünauer Straße 5
12557 Berlin
T: +49 (0)30 347 47 44 14
M: ir@m1-kliniken.de

SCHOTT Pharma delivers on full-year revenue and profitability targets

• Revenue of EUR 986.2m reflects a 5.8% growth at constant currencies
• EBITDA margin at constant currencies increased to 28.4% (prior year: 26.9%)
• Successful expansion of high-value solutions (HVS) – revenue share increased to 57% (prior year: 55%)
• Guidance for FY 2026: 2-5% revenue growth at constant currencies and EBITDA margin of around 27%

SCHOTT Pharma, a pioneer in drug containment solutions and delivery systems, has successfully concluded its fiscal year 2025¹.Revenue rose to EUR 986.2m, representing an increase of 5.8% at constant currencies (reported +3.0%). Full-year EBITDA grew even stronger and amounted to EUR 280.3m, up 11.5% at constant currencies (reported +8.8%). The corresponding EBITDA margin was 28.4% (reported 28.4%).

“Amid the challenging macroeconomic environment, SCHOTT Pharma once again delivered excellent results, and we met our targets for both revenue and profitability. While our core solutions remain a very solid and profitable business, we have effectively continued to focus on increasing the revenue share of our high-value solutions through product innovation, capacity expansions, and strong partnerships,” said SCHOTT Pharma’s CEO Andreas Reisse. “As we expect the market to remain difficult, we target a revenue growth of 2-5% for fiscal year 2026 and an EBITDA margin of around 27%. This represents a bridge year, as we anticipate market dynamics to pick up again going forward. We update our mid-term guidance and now project a revenue CAGR of 6-8% and an incremental increase of our EBITDA margin over the coming years.”

Reinhard Mayer, CFO of SCHOTT Pharma, adds: “The disciplined execution of our strategy in 2025 has further strengthened SCHOTT Pharma’s financial foundation and bolstered our resilience against the backdrop of geopolitical uncertainties. Over the last six years, we have invested around EUR 800m in our global manufacturing network, particularly for high-value solutions. At the same time, we have further improved our efficiency through automation and digitization, which is also reflected in the positive development of our EBITDA margin. Looking ahead, we remain committed to investing in innovation, capacity and operational excellence to drive sustainable, profitable growth alongside our mid-term expectations.”

Profitable growth driven by high-value solutions

SCHOTT Pharma’s positive development was driven by the Drug Containment Solutions segment (DCS), where revenue increased 11.9% at constant currencies (reported +5.6%) to EUR 548.0m. High-value solution products like sterile ready-to-use cartridges and vials as well as specialty vials for innovative biologic drugs performed particularly well. As a consequence, the segment’s HVS revenue share grew by 6pp to 23%. EBITDA in the DCS segment rose to EUR 127.5m, marking a significant surge of 34.9% at constant currencies (reported +26.0%) due to a favorable product mix and efficiency gains. The corresponding margin went up by 4.0pp to 23.5% (reported 23.3%).

Revenue in the Drug Delivery Systems (DDS) segment were at EUR 438.8m, representing a slight decline of 1.3% at constant currencies (reported: 0.0%). The lower demand for polymer syringes was offset by the sustained high demand for prefillable glass syringes. EBITDA decreased by 9.9% at constant currencies (reported -8.2%) to EUR 152.8m, mainly due to lower utilization as well as ramp-up costs for the new prefillable glass syringe manufacturing facility in Hungary. The segment´s EBITDA margin was at 34.6% at constant currencies (reported 34.8%), down 3.3pp on the previous year’s figure.

Solid cash generation and high growth investments

SCHOTT Pharma’s operating cash flow came in at EUR 179.9m in the reporting year, after EUR 224.8m in 2024. This was mainly due to a higher working capital need and timing of tax payments, which more than offset the EBITDA improvement. At EUR 144.8m, CAPEX was on par with the previous year’s level, as the company continued to invest in capacity expansion, particularly for high-value solutions.

Earnings per share for the reporting year were EUR 0.97 (prior year: EUR 0.99). The Management Board and Supervisory Board will propose a dividend of EUR 0.18 per share for FY 2025 at the Annual General Meeting on February 3, 2026. That would result in a payout ratio of 18% of the profit for the period.

Addressing market needs, preparing for future growth

In fiscal year 2025, SCHOTT Pharma launched several product innovations addressing major market trends, such as the increasing demand for solutions that enable the safe and easy self-administration of injectable drugs at home; the growing and increasingly diverse range of sensitive biologics; as well as the need for a more sustainable manufacturing and reliable supply of drugs and vaccines. The portfolio additions include sterile large-volume syringes and cartridges made of glass and polymer, which further strengthen the company’s product range of high-value solutions.

At the same time, SCHOTT Pharma continued to execute its multi-year expansion plan and achieved important milestones. The company opened a new production site in Serbia and celebrated the groundbreaking for a new facility for sterile ready-to-use cartridges in Hungary.

Outlook

SCHOTT Pharma expects revenue growth at constant currencies of 2-5% for fiscal year 2026 and the EBITDA margin to be around 27%. The sales growth will be entirely driven by the DCS segment. At the same time, the DDS segment will be impacted by the unexpected revised market outlook of a key customer resulting in lower glass syringes demand. Product mix effects and a temporary underutilization of capacities in DDS, as well as ramp-up costs for new factories in Serbia and Hungary is impacting the EBITDA margin in 2026.

Based on this, SCHOTT Pharma updates its mid-term outlook for 2027 to 2029 to a revenue CAGR of 6-8% and expects the EBITDA margin to improve over the coming years towards 30%.

New CEO appointed

On November 5, 2025, SCHOTT Pharma announced that Christian Mias will succeed Andreas Reisse as CEO, effective May 1, 2026. Mias has 20 years of management experience, thereof more than 18 years within the SCHOTT group. There, he has held leadership positions across various business units and continents, in which he drove profitable growth by optimizing processes, improving productivity, and increasing earnings quality. His career also included roles at SCHOTT Tubing, which manufactures glass tubing for the pharmaceutical sector, including for SCHOTT Pharma, where he gained significant experience in the pharmaceutical industry.

For additional news about SCHOTT Pharma, please visit our media center.

Key figures FY 2025

Key figures Q4 2025

Differences in the total numbers in the tables may be due to rounding, and differences in group revenue may result from consolidation and reconciliation effects. / nm = not meaningful

¹The fiscal year runs from October to September. Q4 2025 therefore relates to the period from July 2025 to September 2025.
²cc = at constant currencies

Webcast

CEO Andreas Reisse and CFO Reinhard Mayer will speak at an analyst and investor conference call at 11:00 a.m. CET on 11 December 2025 to discuss the Q4 and FY 2025 results. The audio webcast can be followed via the following link. The accompanying presentation is available on the IR website: www.schott-pharma.com/investor-relations

About SCHOTT Pharma

Human health matters. That is why SCHOTT Pharma designs containment solutions grounded in science to ensure that medications are safe and easy to use for people around the world. Every minute, more than 30,000 people receive an injection packed in a SCHOTT Pharma product. The portfolio comprises drug containment solutions and delivery systems for injectable drugs ranging from prefillable glass and polymer syringes to cartridges, vials, and ampoules. Every day, a team of around 4,800 people from over 65 nations works at SCHOTT Pharma to contribute to global health. The company is represented in all main pharmaceutical hubs with 17 manufacturing sites in Europe, North and South America, and Asia. With over 1,000 patents and technologies developed in-house and a state-of-the-art R&D center in Switzerland, the company is focused on developing innovations for the future. Currently, SCHOTT Pharma has over 1,800 customers including the top 30 leading pharma manufacturers for injectable drugs and generated revenue of EUR 986 million in the fiscal year 2025. SCHOTT Pharma AG & Co. KGaA is headquartered in Mainz, Germany and listed on the Frankfurt Stock Exchange as part of the SDAX. It is majority owned by SCHOTT AG, which is owned by the Carl Zeiss Foundation. In light of this spirit, SCHOTT Pharma is committed to sustainable development for society and the environment. Further information at www.schott-pharma.com

Press contact

Lea Kaiser

PR & Communications Manager

Tel.: +49 (0) 151 68917195

E-Mail : lea.kaiser@schott.com

Katrin Schreyer

Global Communications Manager

Tel.: +49 (0) 171 116 7544

E-Mail : katrin.schreyer@schott.com

Investor Relations contact

Tobias Erfurth

Head of Investor Relations

Jasko Terzic

Senior Manager Investor Relations

E-Mail: ir.pharma@schott.com